Revance Therapeutics, Inc. (RVNC): Price and Financial Metrics

Revance Therapeutics, Inc. (RVNC)

Today's Latest Price: $25.96 USD

0.07 (-0.27%)

Updated Oct 28 11:02am

Add RVNC to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

RVNC Stock Summary

  • RVNC's price/sales ratio is 3,370.12; that's higher than the P/S ratio of 99.67% of US stocks.
  • With a year-over-year growth in debt of 555.11%, Revance Therapeutics Inc's debt growth rate surpasses 96.71% of about US stocks.
  • As for revenue growth, note that RVNC's revenue has grown -84.27% over the past 12 months; that beats the revenue growth of only 1.55% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Revance Therapeutics Inc, a group of peers worth examining would be ADVM, AUPH, VTVT, CRMD, and GERN.
  • RVNC's SEC filings can be seen here. And to visit Revance Therapeutics Inc's official web site, go to

RVNC Stock Price Chart Interactive Chart >

Price chart for RVNC

RVNC Price/Volume Stats

Current price $25.96 52-week high $34.62
Prev. close $26.03 52-week low $11.78
Day low $25.01 Volume 97,057
Day high $26.10 Avg. volume 698,140
50-day MA $27.16 Dividend yield N/A
200-day MA $22.80 Market Cap 1.71B

Revance Therapeutics, Inc. (RVNC) Company Bio

Revance Therapeutics is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company was founded in 1999 and is based in Newark, California.

RVNC Latest News Stream

Event/Time News Detail
Loading, please wait...

RVNC Latest Social Stream

Loading social stream, please wait...

View Full RVNC Social Stream

Latest RVNC News From Around the Web

Below are the latest news stories about Revance Therapeutics Inc that investors may wish to consider to help them evaluate RVNC as an investment opportunity.

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...

Benzinga | September 17, 2020

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories (NYSE: ABT ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Fluidigm Corporation (NASDAQ: FLDM ) ( announced emergency use authorization for its saliva-based COVID-19 test) Generation Bio Co (NASDAQ: GBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Ocular Therapeutix Inc (NASDAQ: OCUL ) PPD Inc (NASDAQ: PPD ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Silk Road Medical Inc (NASDAQ: SILK ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Polypid Ltd (NASDAQ: PYPD ) Stocks In Focus FDA Approves Companion Diagnos...

Benzinga | August 27, 2020

The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDA...

Benzinga | August 25, 2020

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2020 Results - Earnings Call Transcript

Revance Therapeutics, Inc. (RVNC) Q2 2020 Earnings Conference Call August 06, 2020 04:30 PM ET Company Participants Jeanie Herbert - Head, Investor Relations & Corporate Communications Mark Foley - President & Chief Executive Officer Dustin Sjuts - Chief Commercial Officer, Aesthetics & Therapeutics Toby Schilke - Chief Financial Officer Abhay...

SA Transcripts on Seeking Alpha | August 9, 2020

Read More 'RVNC' Stories Here

RVNC Price Returns

1-mo -0.12%
3-mo 7.54%
6-mo 49.97%
1-year 68.35%
3-year -0.73%
5-year -33.72%
YTD 59.95%
2019 -19.37%
2018 -43.69%
2017 72.71%
2016 -39.40%
2015 101.65%

Continue Researching RVNC

Here are a few links from around the web to help you further your research on Revance Therapeutics Inc's stock as an investment opportunity:

Revance Therapeutics Inc (RVNC) Stock Price | Nasdaq
Revance Therapeutics Inc (RVNC) Stock Quote, History and News - Yahoo Finance
Revance Therapeutics Inc (RVNC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7822 seconds.